Over the course of Clinical Trial 2, a total of 210 patients from all sites is expected to be enrolled. Each site should enroll 10 patients per year. Any deviations from this number must be approved in writing by the Executive Steering Committee and may result in budget redistribution across sites. Dr. Ikuo Hirano will be the Associate Project Leader for Clinical Trial 2. He will assist Dr. Rothenberg with the overall administration of Clinical Trial 2. He will help with the coordination of CEGIR sites for Clinical Trial 2. The total leadership responsibilities for Clinical Trial 2 will be shared with Dr. Rothenberg and the Associate Project Leaders. Dr. Ikuo Hirano will be working in conjunction with Dr. Barry Wershil at Lurie Children’s Hospital.
|Effective start/end date||8/15/14 → 7/31/19|
- Cincinnati Children's Hospital Medical Center (135409-CT2-Diet Study//5U54AI117804-05 REVISED)
- National Institute of Allergy and Infectious Diseases (135409-CT2-Diet Study//5U54AI117804-05 REVISED)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.